Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications
Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.
Video content above is prompted by the following:
- Briefly comment on the secondary analysis from MARIPOSA evaluating 1L amivantamab + lazertinib vs osimertinib in patients with high-risk advanced EGFR-mutant NSCLC.
- How are you using amivantamab in the 1L and 2L treatment setting?
- How do you select patients for treatment with amivantamab?
Recent Videos
Related Content
Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024Article
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
